{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:33:09Z","timestamp":1792794789573,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-024-05561-5","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T10:02:55Z","timestamp":1725357775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Trends and insights in dengue virus research globally: a bibliometric analysis (1995\u20132023)"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3124-0627","authenticated-orcid":false,"given":"Yumeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MengMeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"5561_CR1","doi-asserted-by":"crossref","unstructured":"Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ et al. Dengue: a continuing global threat. NAT REV MICROBIOL. 2010 2010-12-01;8(12 Suppl):S7\u201316.","DOI":"10.1038\/nrmicro2460"},{"key":"5561_CR2","doi-asserted-by":"crossref","unstructured":"Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017 2017-11-17;358(6365):929\u201332.","DOI":"10.1126\/science.aan6836"},{"key":"5561_CR3","doi-asserted-by":"crossref","unstructured":"Wilder-Smith A, Ooi EE, Horstick O, Wills B, Dengue. LANCET. 2019 2019-01-26;393(10169):350\u2009\u2013\u200963.","DOI":"10.1016\/S0140-6736(18)32560-1"},{"key":"5561_CR4","doi-asserted-by":"crossref","unstructured":"Messina JP, Brady OJ, Golding N, Kraemer M, Wint G, Ray SE et al. The current and future global distribution and population at risk of dengue. NAT MICROBIOL. 2019 2019-09-01;4(9):1508\u201315.","DOI":"10.1038\/s41564-019-0476-8"},{"issue":"33","key":"5561_CR5","first-page":"255","volume":"65","author":"Dengue in the South Pacific","year":"1990","unstructured":"Dengue in the South Pacific. Wkly Epidemiol Rec. 1990;65(33):255\u20136. 1990-08-17.","journal-title":"Wkly Epidemiol Rec"},{"key":"5561_CR6","doi-asserted-by":"crossref","unstructured":"Ng WC, Lin L, Siriphanitchakorn T, Jiang M, Tan HC, Ooi EE. A natural human cell-adapted dengue type 3 virus strain. MICROBIOL SPECTR. 2024 2024-06-07:e70124.","DOI":"10.1128\/spectrum.00701-24"},{"key":"5561_CR7","doi-asserted-by":"crossref","unstructured":"Bifani AM, Siriphanitchakorn T, Choy MM. Intra-host Diversity of Dengue Virus in Mosquito vectors. FRONT CELL INFECT MI. 2022 2022-01-20;12:888804.","DOI":"10.3389\/fcimb.2022.888804"},{"key":"5561_CR8","doi-asserted-by":"crossref","unstructured":"Redoni M, Yacoub S, Rivino L, Giacobbe DR, Luzzati R, Di Bella S, Dengue. Status of current and under-development vaccines. REV MED VIROL. 2020 2020-07-01;30(4):e2101.","DOI":"10.1002\/rmv.2101"},{"key":"5561_CR9","doi-asserted-by":"crossref","unstructured":"Malik S, Ahsan O, Mumtaz H, Tahir KM, Sah R, Waheed Y. Tracing down the Updates on Dengue Virus-Molecular Biology, Antivirals, and Vaccine Strategies. VACCINES-BASEL. 2023 2023-08-05;11(8).","DOI":"10.3390\/vaccines11081328"},{"key":"5561_CR10","doi-asserted-by":"crossref","unstructured":"Yuan K, Chen Y, Zhong M, Lin Y, Liu L. Risk and predictive factors for severe dengue infection: a systematic review and meta-analysis. PLoS ONE. 2022 2022-01-20;17(4):e267186.","DOI":"10.1371\/journal.pone.0267186"},{"key":"5561_CR11","doi-asserted-by":"crossref","unstructured":"Sharp TM, Anderson KB, Katzelnick LC, Clapham H, Johansson MA, Morrison AC et al. Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation. LANCET INFECT DIS. 2022 2022-02-01;22(2):e42\u201351.","DOI":"10.1016\/S1473-3099(20)30871-9"},{"key":"5561_CR12","doi-asserted-by":"crossref","unstructured":"Sharp TM, Fischer M, Munoz-Jordan JL, Paz-Bailey G, Staples JE, Gregory CJ et al. Dengue and Zika Virus Diagnostic Testing for patients with a clinically compatible illness and risk for infection with both viruses. MMWR RECOMM REP. 2019 2019-06-14;68(1):1\u201310.","DOI":"10.15585\/mmwr.rr6801a1"},{"key":"5561_CR13","doi-asserted-by":"crossref","unstructured":"Roy SK, Bhattacharjee S. Dengue virus: epidemiology, biology, and disease aetiology. CAN J MICROBIOL. 2021 2021-10-01;67(10):687\u2013702.","DOI":"10.1139\/cjm-2020-0572"},{"key":"5561_CR14","doi-asserted-by":"crossref","unstructured":"Rapaport S, Maurino M, Morales MA, Fabbri C, Luppo V, Buyayisqui MP et al. Epidemiology of Dengue in Argentina during the 2010\/11 to 2019\/20 Seasons: a contribution to the Burden of Disease. TROP MED INFECT DIS. 2024 2024-02-10;9(2).","DOI":"10.3390\/tropicalmed9020045"},{"key":"5561_CR15","doi-asserted-by":"crossref","unstructured":"Paz-Bailey G, Adams LE, Deen J, Anderson KB, Katzelnick LC, Dengue. LANCET. 2024 2024-02-17;403(10427):667\u2009\u2013\u200982.","DOI":"10.1016\/S0140-6736(23)02576-X"},{"key":"5561_CR16","doi-asserted-by":"crossref","unstructured":"Torres-Flores JM, Reyes-Sandoval A, Salazar MI. Dengue Vaccines: An Update. BIODRUGS. 2022 2022-05-01;36(3):325\u2009\u2013\u200936.","DOI":"10.1007\/s40259-022-00531-z"},{"key":"5561_CR17","doi-asserted-by":"crossref","unstructured":"Huang CH, Tsai YT, Wang SF, Wang WH, Chen YH. Dengue vaccine: an update. EXPERT REV ANTI-INFE. 2021 2021-12-01;19(12):1495\u2013502.","DOI":"10.1080\/14787210.2021.1949983"},{"key":"5561_CR18","doi-asserted-by":"crossref","unstructured":"Liu Z, Zhang Q, Li L, He J, Guo J, Wang Z et al. The effect of temperature on dengue virus transmission by Aedes mosquitoes. FRONT CELL INFECT MI. 2023 2023-01-20;13:1242173.","DOI":"10.3389\/fcimb.2023.1242173"},{"key":"5561_CR19","doi-asserted-by":"crossref","unstructured":"Reed E, Byrd BD, Richards SL, Eckardt M, Williams C, Reiskind MH. A Statewide Survey of Container Aedes mosquitoes (Diptera: Culicidae) in North Carolina, 2016: a Multiagency Surveillance response to Zika Using Ovitraps. J MED ENTOMOL. 2019 2019-02-25;56(2):483\u201390.","DOI":"10.1093\/jme\/tjy190"},{"key":"5561_CR20","doi-asserted-by":"crossref","unstructured":"Liu Z, Zhang Q, Li L, He J, Guo J, Wang Z et al. Corrigendum: the effect of temperature on dengue virus transmission by Aedes mosquitoes. FRONT CELL INFECT MI. 2023 2023-01-20;13:1320461.","DOI":"10.3389\/fcimb.2023.1320461"},{"key":"5561_CR21","doi-asserted-by":"crossref","unstructured":"Prapty C, Rahmat R, Araf Y, Shounak SK, Noor-A-Afrin, Rahaman TI et al. SARS-CoV-2 and dengue virus co-infection: epidemiology, pathogenesis, diagnosis, treatment, and management. REV MED VIROL. 2023 2023-01-01;33(1):e2340.","DOI":"10.1002\/rmv.2340"},{"key":"5561_CR22","doi-asserted-by":"crossref","unstructured":"Kok BH, Lim HT, Lim CP, Lai NS, Leow CY, Leow CH. Dengue virus infection - a review of pathogenesis, vaccines, diagnosis and therapy. VIRUS RES. 2023 2023-01-15;324:199018.","DOI":"10.1016\/j.virusres.2022.199018"},{"key":"5561_CR23","doi-asserted-by":"crossref","unstructured":"Huang Y, Peng Q, Tian X, Chen C, Zhu X, Huang C et al. Nuclear membrane protein SUN2 promotes replication of flaviviruses through modulating cytoskeleton reorganization mediated by NS1. NAT COMMUN. 2024 2024-01-05;15(1):296.","DOI":"10.1038\/s41467-023-44580-6"},{"key":"5561_CR24","doi-asserted-by":"crossref","unstructured":"Vouga M, Chiu YC, Pomar L, de Meyer SV, Masmejan S, Genton B et al. Dengue, Zika and Chikungunya during pregnancy: pre- and post-travel advice and clinical management. J TRAVEL MED. 2019 2019-12-23;26(8).","DOI":"10.1093\/jtm\/taz077"},{"key":"5561_CR25","doi-asserted-by":"crossref","unstructured":"Christie C, Lue AM, Melbourne-Chambers RH. Dengue, Chikungunya and Zika Arbovirus infections in Caribbean children. CURR OPIN PEDIATR. 2023 2023-04-01;35(2):155\u201365.","DOI":"10.1097\/MOP.0000000000001229"},{"key":"5561_CR26","doi-asserted-by":"crossref","unstructured":"Zanotto P, Leite L. The challenges imposed by Dengue, Zika, and Chikungunya to Brazil. FRONT IMMUNOL. 2018 2018-01-20;9:1964.","DOI":"10.3389\/fimmu.2018.01964"},{"key":"5561_CR27","doi-asserted-by":"crossref","unstructured":"Bastos FP, Francisco M, Santos CS, de Almeida BL, Souza M, Ribeiro D et al. High seroprevalence of antibodies against arboviruses in postpartum women in Salvador, Brazil. IJID Reg. 2023 2023-12-01;9:55\u2009\u2013\u20098.","DOI":"10.1016\/j.ijregi.2023.09.004"},{"key":"5561_CR28","doi-asserted-by":"crossref","unstructured":"Teixeira SC, Borges BC, Oliveira VQ, Carregosa LS, Bastos LA, Santos IA et al. Insights into the antiviral activity of phospholipases a(2) (PLA(2)s) from snake venoms. INT J BIOL MACROMOL. 2020 2020-12-01;164:616\u2009\u2013\u200925.","DOI":"10.1016\/j.ijbiomac.2020.07.178"},{"key":"5561_CR29","doi-asserted-by":"crossref","unstructured":"Loaiza-Cano V, Monsalve-Escudero LM, Filho C, Martinez-Gutierrez M, Sousa DP. Antiviral role of Phenolic compounds against Dengue Virus: a review. BIOMOLECULES. 2020 2020-12-24;11(1).","DOI":"10.3390\/biom11010011"},{"key":"5561_CR30","doi-asserted-by":"crossref","unstructured":"Sarker A, Dhama N, Gupta RD. Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement. FRONT IMMUNOL. 2023 2023-01-20;14:1200195.","DOI":"10.3389\/fimmu.2023.1200195"},{"key":"5561_CR31","doi-asserted-by":"crossref","unstructured":"Bournazos S, Gupta A, Ravetch JV. The role of IgG fc receptors in antibody-dependent enhancement. NAT REV IMMUNOL. 2020 2020-10-01;20(10):633\u201343.","DOI":"10.1038\/s41577-020-00410-0"},{"key":"5561_CR32","doi-asserted-by":"crossref","unstructured":"Mikita CP, Padlan EA. Can we find a possible structural explanation for antibody-dependent enhancement of dengue virus infection resulting in hemorrhagic fever? MED HYPOTHESES. 2016 2016-03-01;88:49\u201352.","DOI":"10.1016\/j.mehy.2015.11.006"},{"key":"5561_CR33","doi-asserted-by":"crossref","unstructured":"Chotiwan N, Roehrig JT, Schlesinger JJ, Blair CD, Huang CY. Molecular determinants of dengue virus 2 envelope protein important for virus entry in FcgammaRIIA-mediated antibody-dependent enhancement of infection. Virology. 2014 2014-05-01;456\u2013457:238\u2009\u2013\u200946.","DOI":"10.1016\/j.virol.2014.03.031"},{"key":"5561_CR34","doi-asserted-by":"crossref","unstructured":"Gu W, Guo L, Yu H, Niu J, Huang M, Luo X et al. Involvement of CD16 in antibody-dependent enhancement of porcine reproductive and respiratory syndrome virus infection. J GEN VIROL. 2015 2015-07-01;96(Pt 7):1712\u201322.","DOI":"10.1099\/vir.0.000118"},{"key":"5561_CR35","doi-asserted-by":"crossref","unstructured":"Wilson ME, Chen LH. Dengue: update on epidemiology. CURR INFECT DIS REP. 2015 2015-01-01;17(1):457.","DOI":"10.1007\/s11908-014-0457-2"},{"key":"5561_CR36","doi-asserted-by":"crossref","unstructured":"Bigay J, Le Grand R, Martinon F, Maisonnasse P. Vaccine-associated enhanced disease in humans and animal models: lessons and challenges for vaccine development. FRONT MICROBIOL. 2022 2022-01-20;13:932408.","DOI":"10.3389\/fmicb.2022.932408"},{"key":"5561_CR37","doi-asserted-by":"crossref","unstructured":"Wang WH, Urbina AN, Lin CY, Yang ZS, Assavalapsakul W, Thitithanyanont A et al. Targets and strategies for vaccine development against dengue viruses. BIOMED PHARMACOTHER. 2021 2021-12-01;144:112304.","DOI":"10.1016\/j.biopha.2021.112304"},{"key":"5561_CR38","doi-asserted-by":"crossref","unstructured":"Blaney JJ, Durbin AP, Murphy BR, Whitehead SS. Development of a live attenuated dengue virus vaccine using reverse genetics. VIRAL IMMUNOL. 2006 2006-03-01;19(1):10\u201332.","DOI":"10.1089\/vim.2006.19.10"},{"key":"5561_CR39","doi-asserted-by":"crossref","unstructured":"Biswal S, Borja-Tabora C, Martinez VL, Velasquez H, Theresa AM, Sierra V et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial. Lancet. 2020 2020-05-02;395(10234):1423\u201333.","DOI":"10.1016\/S0140-6736(20)30414-1"},{"key":"5561_CR40","doi-asserted-by":"crossref","unstructured":"Pintado SJ, Fernandez-Sesma A. Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art. J GEN VIROL. 2023 2023-03-01;104(3).","DOI":"10.1099\/jgv.0.001831"},{"issue":"9951","key":"5561_CR41","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","volume":"384","author":"MR Capeding","year":"2014","unstructured":"Capeding MR, Tran NH, Hadinegoro S, Ismail H, Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358\u201365.","journal-title":"Lancet"},{"key":"5561_CR42","doi-asserted-by":"crossref","unstructured":"Salje H, Alera MT, Chua MN, Hunsawong T, Ellison D, Srikiatkhachorn A et al. Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection. NAT MED. 2021 2021-01-01;27(8):1395.","DOI":"10.1038\/s41591-021-01392-9"},{"key":"5561_CR43","doi-asserted-by":"crossref","unstructured":"Li S, Li H, Lian R, Xie J, Feng R. New perspective of small-molecule antiviral drugs development for RNA viruses. Virology. 2024 2024-03-07;594:110042.","DOI":"10.1016\/j.virol.2024.110042"},{"key":"5561_CR44","doi-asserted-by":"crossref","unstructured":"Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLOS NEGLECT TROP D. 2010 2010-08-10;4(8):e785.","DOI":"10.1371\/journal.pntd.0000785"},{"issue":"9","key":"5561_CR45","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/infdis\/jis470","volume":"207","author":"NM Nguyen","year":"2013","unstructured":"Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh HA, Farrar J, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J INFECT DIS. 2013;207(9):1442\u201350. 2013-05-01.","journal-title":"J INFECT DIS"},{"key":"5561_CR46","doi-asserted-by":"crossref","unstructured":"Boldescu V, Behnam M, Vasilakis N, Klein CD. Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond. NAT REV DRUG DISCOV. 2017 2017-08-01;16(8):565\u201386.","DOI":"10.1038\/nrd.2017.33"},{"key":"5561_CR47","doi-asserted-by":"crossref","unstructured":"Fox T, Sguassero Y, Chaplin M, Rose W, Doum D, Arevalo-Rodriguez I et al. Wolbachia-carrying Aedes mosquitoes for preventing dengue infection. COCHRANE DB SYST REV. 2024 2024-04-10;4(4):CD15636.","DOI":"10.1002\/14651858.CD015636.pub2"},{"issue":"1","key":"5561_CR48","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1038\/s41467-021-24654-z","volume":"12","author":"GH Wang","year":"2021","unstructured":"Wang GH, Gamez S, Raban RR, Marshall JM, Alphey L, Li M, et al. Combating mosquito-borne diseases using genetic control technologies. NAT COMMUN. 2021;12(1):4388. 2021-07-19.","journal-title":"NAT COMMUN"},{"key":"5561_CR49","doi-asserted-by":"crossref","unstructured":"Athanassiou CG, Kavallieratos NG, Benelli G, Losic D, Rani PU, Desneux N. Nanoparticles for pest control: current status and future perspectives. J PEST SCI. 2018 2018-01-01;91(1):1\u201315.","DOI":"10.1007\/s10340-017-0898-0"},{"key":"5561_CR50","doi-asserted-by":"crossref","unstructured":"Carrasco-Escobar G, Moreno M, Fornace K, Herrera-Varela M, Manrique E, Conn JE. The use of drones for mosquito surveillance and control. PARASITE VECTOR. 2022;15(1).","DOI":"10.1186\/s13071-022-05580-5"},{"key":"5561_CR51","doi-asserted-by":"crossref","unstructured":"Sebastianelli A, Spiller D, Carmo R, Wheeler J, Nowakowski A, Jacobson LV et al. A reproducible ensemble machine learning approach to forecast dengue outbreaks. SCI REP-UK. 2024 2024-02-15;14(1):3807.","DOI":"10.1038\/s41598-024-52796-9"},{"key":"5561_CR52","doi-asserted-by":"crossref","unstructured":"Williams CR, Mincham G, Ritchie SA, Viennet E, Harley D. Bionomic response of Aedes aegypti to two future climate change scenarios in far north Queensland, Australia: implications for dengue outbreaks. PARASITE VECTOR. 2014 2014-09-19;7:447.","DOI":"10.1186\/1756-3305-7-447"},{"key":"5561_CR53","doi-asserted-by":"crossref","unstructured":"Randhawa N, Mailhot H, Lang DT, Martinez-Lopez B, Gilardi K, Mazet J. Fine scale infectious disease modeling using satellite-derived data. SCI REP-UK. 2021 2021-03-25;11(1):6946.","DOI":"10.1038\/s41598-021-86124-2"},{"key":"5561_CR54","doi-asserted-by":"crossref","unstructured":"Castillo RJ, Urcuqui-Inchima S. Dengue Virus Control of Type I IFN responses: a history of Manipulation and Control. J INTERF CYTOK RES. 2015 2015-06-01;35(6):421\u201330.","DOI":"10.1089\/jir.2014.0129"},{"key":"5561_CR55","doi-asserted-by":"crossref","unstructured":"Chazal M, Beauclair G, Gracias S, Najburg V, Simon-Loriere E, Tangy F et al. RIG-I Recognizes the 5\u2019 Region of Dengue and Zika Virus Genomes. CELL REP. 2018 2018-07-10;24(2):320\u20138.","DOI":"10.1016\/j.celrep.2018.06.047"},{"key":"5561_CR56","unstructured":"DENV host interaction. and altered antiviral pathway during DENV infection."},{"key":"5561_CR57","doi-asserted-by":"crossref","unstructured":"Serrato-Salas J, Izquierdo-Sanchez J, Arguello M, Conde R, Alvarado-Delgado A, Lanz-Mendoza H. Aedes aegypti antiviral adaptive response against DENV-2. DEV COMP IMMUNOL. 2018 2018-07-01;84:28\u201336.","DOI":"10.1016\/j.dci.2018.01.022"},{"key":"5561_CR58","doi-asserted-by":"crossref","unstructured":"Siriphanitchakorn T, Kini RM, Ooi EE, Choy MM. Revisiting dengue virus-mosquito interactions: molecular insights into viral fitness. J GEN VIROL. 2021 2021-11-01;102(11).","DOI":"10.1099\/jgv.0.001693"},{"key":"5561_CR59","doi-asserted-by":"crossref","unstructured":"Khanam A, Gutierrez-Barbosa H, Lyke KE, Chua JV. Immune-mediated pathogenesis in Dengue Virus infection. VIRUSES-BASEL. 2022 2022-11-21;14(11).","DOI":"10.3390\/v14112575"},{"key":"5561_CR60","doi-asserted-by":"crossref","unstructured":"Cruz-Oliveira C, Freire JM, Conceicao TM, Higa LM, Castanho MA, Da PA. Receptors and routes of dengue virus entry into the host cells. FEMS MICROBIOL REV. 2015 2015-03-01;39(2):155\u201370.","DOI":"10.1093\/femsre\/fuu004"},{"key":"5561_CR61","unstructured":"Transmission. dynamics."},{"issue":"1","key":"5561_CR62","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12929-024-01030-9","volume":"31","author":"S Sinha","year":"2024","unstructured":"Sinha S, Singh K, Ravi KY, Roy R, Phadnis S, Meena V, et al. Dengue virus pathogenesis and host molecular machineries. J BIOMED SCI. 2024;31(1):43. 2024-04-22.","journal-title":"J BIOMED SCI"},{"issue":"10422","key":"5561_CR63","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0140-6736(24)00046-1","volume":"403","author":"L Alves","year":"2024","unstructured":"Alves L. Brazil to start widespread dengue vaccinations. Lancet. 2024;403(10422):133. 2024-01-13.","journal-title":"Lancet"},{"key":"5561_CR64","doi-asserted-by":"crossref","unstructured":"Izmirly AM, Pelletier AN, Connors J, Taramangalam B, Alturki SO, Gordon EA et al. Pre-vaccination frequency of circulatory tfh is associated with robust immune response to TV003 dengue vaccine. PLOS PATHOG. 2022 2022-01-01;18(1):e1009903.","DOI":"10.1371\/journal.ppat.1009903"},{"issue":"24","key":"5561_CR65","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1177\/15353702231151241","volume":"247","author":"SJ Pintado","year":"2022","unstructured":"Pintado SJ, Fenutria R, Bernal-Rubio D, Sanchez-Martin I, Hunziker A, Chebishev E, et al. The dengue virus 4 component of NIAID\u2019s tetravalent TV003 vaccine drives its innate immune signature. EXP BIOL MED. 2022;247(24):2201\u201312. 2022-12-01.","journal-title":"EXP BIOL MED"},{"key":"5561_CR66","doi-asserted-by":"crossref","unstructured":"Huang Z, Zhang Y, Li H, Zhu J, Song W, Chen K et al. Vaccine development for mosquito-borne viral diseases. FRONT IMMUNOL. 2023 2023-01-20;14:1161149.","DOI":"10.3389\/fimmu.2023.1161149"},{"key":"5561_CR67","doi-asserted-by":"crossref","unstructured":"Coronel-Martinez DL, Park J, Lopez-Medina E, Capeding MR, Bonfanti AAC, Montalban MC et al. Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9\u201350 years: a randomised, controlled, phase 2, non-inferiority study. LANCET INFECT DIS. 2022 2022-01-01;22(6):901\u201311.","DOI":"10.1016\/S1473-3099(21)00706-4"},{"key":"5561_CR68","doi-asserted-by":"crossref","unstructured":"Tricou V, Eyre S, Ramjee M, Collini P, Mojares Z, Loeliger E et al. A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country. VACCINE. 2023 2023-02-10;41(7):1398\u2013407.","DOI":"10.1016\/j.vaccine.2023.01.007"},{"key":"5561_CR69","doi-asserted-by":"crossref","unstructured":"Patel SS, Winkle P, Faccin A, Nordio F, LeFevre I, Tsoukas CG. An open-label, phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life. HUM VACC IMMUNOTHER. 2023 2023-08-01;19(2):2254964.","DOI":"10.1080\/21645515.2023.2254964"},{"key":"5561_CR70","doi-asserted-by":"crossref","unstructured":"de Silva A, White L. Immunogenicity of a live Dengue Vaccine (TAK-003). J INFECT DIS. 2022 2022-12-28;227(1):163\u20134.","DOI":"10.1093\/infdis\/jiac424"},{"key":"5561_CR71","doi-asserted-by":"crossref","unstructured":"White LJ, Young EF, Stoops MJ, Henein SR, Adams EC, Baric RS et al. Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003). PLOS NEGLECT TROP D. 2021 2021-03-01;15(3):e9258.","DOI":"10.1371\/journal.pntd.0009258"},{"key":"5561_CR72","doi-asserted-by":"crossref","unstructured":"Wilder-Smith A. TAK-003 dengue vaccine as a new tool to mitigate dengue in countries with a high disease burden. LANCET GLOB HEALTH. 2024 2024-02-01;12(2):e179\u201380.","DOI":"10.1016\/S2214-109X(23)00590-9"},{"key":"5561_CR73","doi-asserted-by":"crossref","unstructured":"Tricou V, Yu D, Reynales H, Biswal S, Saez-Llorens X, Sirivichayakul C et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. LANCET GLOB HEALTH. 2024 2024-02-01;12(2):e257\u201370.","DOI":"10.1016\/S2214-109X(23)00522-3"},{"key":"5561_CR74","doi-asserted-by":"crossref","unstructured":"Zhou X, Lickliter J, Montrond M, Ishak L, Pietropaolo K, James D et al. First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus. ANTIMICROB AGENTS CH. 2024 2024-03-25:e161523.","DOI":"10.1101\/2024.01.03.24300771"},{"key":"5561_CR75","doi-asserted-by":"crossref","unstructured":"Kesteleyn B, Bonfanti JF, Bardiot D, De Boeck B, Goethals O, Kaptein S et al. Discovery of JNJ-1802, a first-in-class Pan-serotype Dengue Virus NS4B inhibitor. J MED CHEM. 2024 2024-03-14;67(5):4063\u201382.","DOI":"10.1021\/acs.jmedchem.3c02336"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05561-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05561-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05561-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T22:03:11Z","timestamp":1725400991000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05561-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5561"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05561-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that has no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"818"}}